search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


5 year follow-up after treatment with radiofrequency ablation for Barrett's esophagus containing HGIN or early cancer.


- candidate number9733
- NTR NumberNTR2938
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-jun-2011
- Secondary IDs10/326 METC AMC
- Public Title5 year follow-up after treatment with radiofrequency ablation for Barrett's esophagus containing HGIN or early cancer.
- Scientific TitleRadiofrequency Ablation with or without Endoscopic Resection for Barrett’s Esophagus containing High-Grade Intraepithelial Neoplasia and/or Early Cancer: Durability of the Post-Treatment Neosquamous Epithelium at 5-year Follow-up.
- ACRONYM
- hypothesisWe hypothesize that radiofrequency ablation (RFA) is safe and effective after 5-year follow-up, for the eradication of Barrett's esophagus (BE) containing neoplasia.
- Healt Condition(s) or Problem(s) studiedBarrett's esophagus, Barrett's neoplasia, Barrett's cancer, Barrett's dysplasia, Radiofrequency ablation
- Inclusion criteria1. All eligible patients treated with RFA (AMC-I/II, AMC-IV and EURO-I), according to the aforementioned study protocols, who are now being followed-up endoscopically in the AMC or referral centre within the Netherlands;
2. Written informed consent.
- Exclusion criteriaNo justification for further follow-up due to (unrelated) comorbidity, or otherwise.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-apr-2011
- planned closingdate1-mei-2012
- Target number of participants55
- Interventions1. Endoscopic surveillance with biopsies according to the Seattle protocol;
2. EUS;
3. Endoscopic resection of the neosquamous epithelium.
- Primary outcome1. Rate of complete histological remission of dysplasia and cancer at 5-yr follow-up;
2. Rate of complete endoscopic and histological eradication of IM (including biopsies obtained from neosquamous mucosa) at 5-year follow-up.
- Secondary outcome1. Prevalence of subsquamous IM in neosquamous biopsies and ER-specimens;
2. Prevalence of IM below the Neo Z-line during 5-year follow-up visits;
3. Adverse events.
- TimepointsT=60: Single visit at 5-year follow up after the first treatment session.
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESProf. dr. J.J.G.H.M. Bergman
- CONTACT for SCIENTIFIC QUERIESProf. dr. J.J.G.H.M. Bergman
- Sponsor/Initiator Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
- Funding
(Source(s) of Monetary or Material Support)
BÂRRX Medical Inc. Sunnyvale, California, US
- Publications1. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, Ten KF, Fockens P, Bergman JJ. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370-379;
2. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, Krishnadath KK, Ten KF, Fockens P, Bergman JJ. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008;40:359-369. 3.Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, Meijer SL, van Berge Henegouwen MI, Weusten BL, Schoon EJ, Mallant-Hent RC, Bergman JJ. Gastroenterology. 2013 Mar 28. pii: S0016-5085(13)00460-5 (Epub ahead of print)
- Brief summaryThe purpose of this project is to report on the 5-year outcomes of 4 previously published, IRB-approved, single-centre pilot trials (AMC-I/II/IV and EURO-I), evaluating long-term safety and efficacy of radiofrequency ablation for eradication of BE containing high-grade intraepithelial neoplasia or early cancer.
- Main changes (audit trail)
- RECORD14-jun-2011 - 15-jun-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl